Does Fetal Fibronectin and Ultrasound Cervical Length Help in the Evaluation of Women With Suspected Preterm Labor?
NCT ID: NCT00371046
Last Updated: 2007-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2003-10-31
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We performed a randomized trial of the use of transvaginal ultrasound cervical length and fetal fibronectin in women being evaluated for suspected PTL at a gestational age between 24 and 33 weeks 6 days. Women are randomized to either a standard (blinded) or a protocol arm. Women in the standard arm are evaluated without the results of the CL and FFN while women in the protocol arm are evaluated using the results of the CL and FFN and managing physicians are asked to follow a specific PTL algorithm to determine a women's eligibility for treatment. The primary outcome is length of stay in the triage area before discharge.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prediction of Preterm Delivery with Serial Cervical Length Measurements After Threatened Preterm Labor
NCT05044143
Universal Transvaginal Cervical Length Screening Program for Prevention of Preterm Birth in Singletons Without Prior Preterm Birth
NCT03591042
The Prognostic Value of Cervical Elastography for Identifying Patients at Risk for Preterm Delivery
NCT02021539
Cervical Softening and the Prediction of Preterm Birth
NCT05477381
Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy Without Prior Spontaneous Preterm Birth
NCT02928302
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective of this study was to investigate the effect of the use of both sonographic cervical length and fetal fibronectin on the length of outpatient triage and preterm labor interventions in symptomatic women with intact membranes.
Methods:
Study design This is a randomized trial of the use of transvaginal ultrasound cervical length and fetal fibronectin in women being evaluated for suspected PTL on labor and delivery at the Thomas Jefferson University Hospital, Philadelphia between November 2004 and April 2006. The study was approved by the Internal Review Board.
Gestational age was assigned by last menstrual period and first or early second trimester ultrasound. If the last menstrual period was unknown or there was a discrepancy regarding the dates, the ultrasound dating was used. Eligible women who agreed to participate in the study were randomized to either a standard or a protocol arm. At the time this study was initiated neither FFN nor CL were routinely used in the management of symptomatic women presenting to L\&D to be evaluated for PTL. Women in the standard arm were evaluated without the results of the CL and FFN while women in the protocol arm were evaluated using the of the CL and FFN and managing physicians were asked to follow a specific PTL algorithm to determine a women's eligibility for treatment. Physicians were encouraged to manage protocol patients according to the study recommended protocol for the use of FFN and CL, which was reviewed with them for each patient on labor and delivery by a study investigator. Once eligible for treatment, the management of PTL was then left to the discretion of the physician.
Definitions and study procedures
Before randomization all patients being evaluated for preterm labor were monitored in the triage area and uterine activity and fetal heart rate evaluated. A speculum exam was performed to rule out ruptured membranes and to obtain a specimen for fetal fibronectin. Specimens for fetal fibronectin were obtained with a Dacron swab from the posterior vaginal fornix and placed in buffer which then held on labor and delivery until the patient was either randomized, determined to be ineligible or declined to participate in the study. After randomization the specimen was immediately analyzed in our in house laboratory. Samples were delivered to the laboratory within 1 hour of obtaining the sample and results were available within 1 hour. Samples containing 50 ng or more per milliliter were designated as positive. The FFN was delayed for 24-36 hours as needed if the patient had intercourse, a pelvic exam or a transvaginal ultrasound within 24 hours. A digital exam was then performed to determine dilatation and effacement of the cervix.
Results of the fibronectin analysis were labeled by one of the study investigators after randomization so that only results from non-blinded specimens would be available to the managing physicians.
Randomization was performed by means of computer generated random blocks of numbered sealed opaque envelops which were stratified in two groups based on gestational age \< 28 weeks and ≥ 28 weeks. Each envelope was opened sequentially within each strata by one of the study investigators.
Following randomization, transvaginal ultrasound assessment of the cervix was performed. Measurements were obtained using a 5-7.5 Mhz transvaginal probe placed in the anterior fornix after emptying the bladder. The transducer was oriented to obtain a sagittal view of the cervix, with the long axis view of the echogenic endocervical mucosa along the length of the canal. The probe was withdrawn slightly until the image was blurred, and enough pressure then reapplied to restore the image. CL was measured from the internal to the external os along the endocervical canal. At least three measurements were recorded over 5 minutes and the shortest best measurement in millimeters was used for the study.
Using a two-sided t-test with alpha of 0.05, we calculated that a sample size of 45 patients in each group would have an 80% power to detect a 1 hour (33%) in the mean time on labor \& delivery (from 3.0 hrs to 2.0 hrs, assuming a standard deviation of 1.0). These assumptions were based on a survey taken from the Labor and Delivery triage database for the 6 months prior to the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transvaginal ultrasound cervical length
Cervicovaginal fetal fibronectin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. contractions ≥ 6/hr, uterine irritability, or symptoms such as cramping, pressure, backache with or without documented contractions which prompted evaluation for PTL
3. cervical dilatation \< 3cm and \< 100% effacement
4. intact membranes.
Exclusion Criteria
2. known congenital anomaly
3. triplets or greater;
4. vaginal bleeding
5. cervical dilatation ≥ 3cm or complete effacement;
6. cerclage
7. known short cervix Women transferred on tocolytics were also excluded
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thomas Jefferson University
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amen Ness, MD
Role: PRINCIPAL_INVESTIGATOR
Thomas Jefferson University
Vincenzo Berghella, MD
Role: STUDY_DIRECTOR
Thomas Jefferson University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
O4U.289
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.